Biopharma industry in decline – drop off is more severe than anyone expected and they are lacking revenue.
Deloitte pharma study: Drop-off in returns on R&D investments – sharp decline in peak sales per asset Zurich/Geneva, 23 January 2023 https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html
Here are the key findings: The top 20 global pharmaceutical companies collectively spent $139 billion on research and development in 2022, down two per cent from 2021. The average projected return on investment (ROI) from research and development fell to 1.2 per cent in 2022, its lowest level since the study was launched in 2010. The average development time for a new drug (from starting clinical trials to approval) increased from 6.9 years in 2021 to 7.1 years, the second longest since the study began. Due to the longer development times, the average cost of developing a new drug rose by $298 million to $2.3 billion in 2022. Average forecast peak sales per asset stood at $389 million in 2022, down from $500 million in 2021. The proportion of forecast revenue from assets co-developed by several companies more than halved year-on-year, falling from 46 per cent in 2021 to just 18 per cent in 2022. Thoughts on the findings and the Swiss pharmaceutical industry: “A decrease in returns from R&D investments was unavoidable in 2021, an unprecedented year marked by the COVID pandemic. However, no one expected the drop-off to be quite so severe. Even without the COVID-19 vaccines and treatments, ROI was still twice as high in 2021 as in 2022,” explains Nico Kleyn, Managing Partner Life Sciences and Health Care for Switzerland and North and South Europe (NSE). “Our analysis shows that the development of new treatments is taking longer and is costing more, and that they are generating less revenue. The research departments of pharmaceutical companies therefore need to transform the clinical trials process,” explains Alexander Mirow, partner and Consulting Industry Lead for Life Sciences at Deloitte Switzerland.